CONCLUSION:
This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7
R Samadi, S Soluti, R Daneshmand, S Assari and AA Manteghi,
Iranian journal of medical sciences , Jan 2017
Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012-2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4-8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler's Adult Intelligence Scale-Revised (WAIS-R), and Hamilton's Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atP<0.05.Ondansetron plus risperidone was associated with a significantly larger improvement in the PANSS overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (P<0.001). The WAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05). Ondansetron had no positive effects on depressive symptoms (effect size=0.13).This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7.
Anon10
March 16, 2017, 1:03pm
2
already existing drugs like odansetron I have given up on. everything is supposed to cure negative symptoms a little, even benzos. We need a drug which has not been repurposed, something made specifically for this need. And we need it now.
min 101 is supposed to treat negative symptoms …!!! 2020 …!!
1 Like
Anon10
March 16, 2017, 1:08pm
4
min-101 is not a new medication though, it is a 5ht2a antagonist, every new antipsychotic does that. I want a new negative symptoms drug not one which has been done before
1 Like
Same here bro we need new formula …!!!
1515151515
1 Like
Anon10
March 16, 2017, 1:09pm
6
How was ur day @far_cry0 ? What time is it in nepal?
1 Like
:Good morning evi buds its exactly 7:00 pm here in the kathmandu …!!! hope u had a good breakfast …!!!1
1 Like
Anon10
March 16, 2017, 1:17pm
8
Thanks, and you have a good dinner and a good night yourself.
1 Like
thanks my good friend have a lovely day a head .!!!
1 Like